Formulation Development and Evaluation of Cost-Effective Sucralfate Oral Suspension: A Comprehensive Review

References

[1] Bighley L, Giesing D. Mechanism of action studies of sucralfate. In: Caspary W, editor. Duodenal Ulcer, Gastric Ulcer: Sucralfate - A New Therapeutic Concept. Munich: Urban & Schwarzenberg; 1981. p. 3-12.

[2] Hollander D, Tarnawski A, Gergely H, et al. Sucralfate protection of the gastric mucosa against ethanol-induced injury: a prostaglandin-mediated process? Scand J Gastroenterol. 1984;19:97-102.

[3] Fromm D. Role of sucralfate in peptic disease [review]. Available from: PubMed (PMID 1611711).

[4] Kobayashi M, et al. A thin layer of sucrose octasulfate protects the oesophageal mucosal epithelium in reflux oesophagitis. Available from: PubMed Central (PMC6401014).

[5] Sucralfate - an overview. ScienceDirect Topics [neuroscience collection]. Elsevier.

[6] Sucralfate-containing composition and process for the preparation thereof. United States Patent (US 6,555,137).

[7] Wang TC. Natural suspending agent including a synergistic blend of xanthan gum and konjac powder for oral pharmaceutical suspensions. United States Patent Application US 2016/0051684 A1; and related granted patent US 9,737,609.

[8] Pharmaceutical Suspensions: An Updated Patent Review on Novel Suspending Agents and Recent Advancement. Recent Patents on Drug Delivery & Formulation [Bentham Science/Eureka Select]; 2023.

[9] Compatibility of Commonly Used Active Pharmaceutical Ingredients in a Ready-to-Use Oral Suspending Vehicle. Pharmaceutics. Available from: PubMed Central (PMC10609746).

[10] Amore BM, Patel N, Batheja P, Templeton IE, Jones HM, Louie MJ, Emery MG. Physiologically Based Pharmacokinetic Model Development and Verification for Bioequivalence Testing of Bempedoic Acid Oral Suspension and Reference Tablet Formulation. Pharmaceutics. 2023;15(5):1476.

[11] Pharmaceutical Suspension: A Review. ResearchGate preprint; 2022.

[12] Chemotherapeutic pharmaceutical suspension for oral dosage [suspending agent formulation]. United States Patent.

[13] Quetiapine oral liquid suspension and use thereof. United States Patent (US 11,813,269; related US 11,045,481).

[14] Exploring paediatric oral suspension development: Challenges, requirements, and formulation advancements. International Journal of Pharmaceutics/ScienceDirect; 2024.

[15] Effectiveness of Sucralfate comparing to normal saline as an oral rinse in pain reduction and wound healing promotion in oral surgery. Available from: PubMed Central (PMC10601550).

[16] DailyMed. Sucralfate Oral Suspension - Prescribing Information. U.S. National Library of Medicine.

[17] Soylu Ozler G, Okuyucu S, Akoglu E. The Efficacy of Sucralfate and Chlorhexidine as an Oral Rinse in Patients with Recurrent Aphthous Stomatitis. BioMed Research International. 2014;2014:986203.

[18] Criticality of functional excipients and decoding methods during generic product development. Pharmaceutical Technology.

[19] Selection of Excipients in Generic Formulations. Pharmaceutical Technology.

[20] Unlocking Cost-Effective Generic Formulation Development: Octavius Pharma's Proven Approach. Octavius Pharma Insights.

[21] Key Considerations for Generic Formulation Development. Pharma Digests; 2024.

[22] The Real Cost of Generic Drug Production: A Full-Stack Analysis. DrugPatentWatch.

[23] Science Behind Excipient Selection in Wet Granulation. Pharma Lesson; 2025.

[24] Generic Drug Cost Optimization: Cut Production Costs, Win Patent Races, and Dominate the Market. DrugPatentWatch.

[25] Fix the Formula to Win the Generic Race: Overcoming Formulation Challenges in Generic Drug Development. DrugPatentWatch.

[26] Formulation and Evaluation of Suspensions: Mefenamic Acid Prodrugs. Pakistan Journal of Pharmaceutical Sciences. 2014;27(4):917-923.

[27] A Review: Pharmaceutical Suspension and its Advancement. ResearchGate preprint; 2023.

[28] Formulation and Evaluation of Nimesulide Suspension. Semantic Scholar repository.

[29] Pharmaceutical Suspension [educational slide presentation]. SlideShare.

[30] Evaluation of Aloe elegans Mucilage as a Suspending Agent in Paracetamol Suspension. Available from: PubMed Central (PMC8349256).

[31] Evaluation of Suspension: Pharmaceutics. ThePharmapedia educational resource.

[32] Evaluation of Grewia ferruginea Hochst ex A. Rich Mucilage as Suspending Agent in Metronidazole Benzoate Suspension. Available from: PubMed Central (PMC7644311).

[33] Rheology of Suspensions Thickened by Cellulose Nanocrystals. Available from: PubMed Central (PMC11243218).

[34] ICH Q1 Stability Testing Guidelines. MasterControl Quality Glossary.

[35] Guidance for Industry: Q1A(R2) Stability Testing of New Drug Substances and Products. U.S. Food and Drug Administration; 2003.

[36] Use of Factorial Designs to Reduce Stability Studies for Parenteral Drug Products: Determination of Factor Effects via Accelerated Stability Data Analysis. Available from: PubMed Central (PMC12389050).

[37] Drug Stability: ICH versus Accelerated Predictive Stability Studies. Available from: PubMed Central (PMC9693625).

[38] Draft ICH Q1 Guideline: Stability Testing of Drug Substances and Drug Products. European Medicines Agency.

[39] Q1A(R2) Stability Testing of New Drug Substances and Products. U.S. Food and Drug Administration, Regulatory Information.

[40] Q1A(R2) Guideline. International Council for Harmonisation database (ich.org).

[41] Sucralfate (Iselpin) 1 g Tablet - Prescribing Information. Pfizer Labeling.

[42] Sucralfate (Sucrose octasulfate-aluminum complex). MedChemExpress product monograph.

[43] Sucralfate: uses, dosing, warnings, adverse events, interactions. MedCentral drug monograph.

[44] Sucralfate - an overview. ScienceDirect Topics [pharmacology, toxicology and pharmaceutical science collection]. Elsevier.

[45] Aluminum complex of polysulfonated sucrose. United States Patent (US 5,084,446).

[46] Sucrosofate - an overview. ScienceDirect Topics. Elsevier.

[47] Sucralfate. In: StatPearls. Treasure Island (FL): StatPearls Publishing; NCBI Bookshelf (NBK551527).

[48] The role of sucralfate oral suspension in prevention of radiation induced mucositis [review]. Academia.edu repository.

[49] The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. Cochrane Central Register of Controlled Trials.

[50] The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 1994.

[51] Dodd MJ, Miaskowski C, Greenspan D, MacPhail L, Shih AS, Shiba G, et al. Radiation-induced mucositis: a randomized clinical trial of micronized sucralfate versus salt & soda mouthwashes. Cancer Invest. 2003;21:21-33.

[52] Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. Available from: PubMed (PMID 3050005).

[53] Sucralfate in the prevention of radiation-induced oral mucositis. Available from: PubMed (PMID 9916664).

[54] A randomized phase III trial of magic mouthwash and sucralfate versus benzydamine hydrochloride for prophylaxis of radiation-induced oral mucositis in head and neck cancer. Journal of Clinical Oncology. 2011;29(15_suppl):5521.

[55] ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients [clinical trial protocol]. Galera Therapeutics, Inc.

[56] The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. Available from: PubMed (PMID 8113113).

[57] The Development of a Chocolate-Based Chewable Tablet of Prednisolone - Enhancing the Palatability of Steroids for Paediatric Use. Available from: PubMed Central (PMC11359696).

[58] Palatability and Stability Studies to Optimize a Carvedilol Oral Liquid Formulation for Paediatric Use. Available from: PubMed Central (PMC10820228).

[59] Vigabatrin liquid pharmaceutical composition. United States Patent (US 12,290,499).

[60] Development of a Hydroxypropyl-beta-Cyclodextrin-Based Liquid Formulation for the Oral Administration of Propranolol in Paediatric Therapy. Available from: PubMed Central (PMC10534794).

[61] Overcoming Challenges in Paediatric Formulation with a Patient-Centric Design Approach: A Proof-of-Concept Study on the Design of an Oral Solution of a Bitter Drug. Available from: PubMed Central (PMC9694284).

[62] Taste Masking Technologies in Oral Pharmaceuticals: Recent Developments and Approaches. Drug Development and Industrial Pharmacy [Taylor & Francis].

[63] Sweetener content and cariogenic potential of pediatric oral medications: A literature review. Available from: PubMed Central (PMC5969777).

[64] Quality-by-design driven approach in the formulation of an anti-ulcer and gastro-protective oral suspension. Drug Development and Industrial Pharmacy. 2024;50(7).

[65] Preformulation Study of Carbamazepine Orally Disintegrating Tablets for Pediatric Patients Using Direct Compression and the SeDeM Diagram Tool: A Quality by Design Approach. Pharmaceutics. 2025;17(5):624.

[66] A Cost Effective (QbD) Approach in the Development and Optimization of Rosiglitazone Maleate Mucoadhesive Extended Release Tablets - In Vitro and Ex Vivo. Available from: PubMed Central (PMC6664114).

[67] Design and Optimization of Lornoxicam Dispersible Tablets Using Quality by Design (QbD) Approach. Available from: PubMed Central (PMC9785951).

[68] Applying QbD to Excipient Formulation and Development. Pharmaceutical Technology.

[69] Quality by Design Based Formulation Study of Meloxicam-Loaded Polymeric Micelles for Intranasal Administration. Available from: PubMed Central (PMC7464185).

[70] Quality by Design and In Silico Approach in SNEDDS Development: A Comprehensive Formulation Framework. Available from: PubMed Central (PMC12195909).

[71] Quality by Design (QbD) Approach used in Development of Pharmaceutical Formulations. ResearchGate preprint.

[72] Implementation of Quality by Design (QbD) for development of bilayer tablets. International Journal of Pharmaceutics/ScienceDirect.

[73] Integrated Quality by Design Approach for Developing Nanolipidic Drug Delivery Systems of Olmesartan Medoxomil with Enhanced Antihypertensive Action. Available from: PubMed Central (PMC7335990).

[74] Indian Pharmacopoeia 2018. Volume II. Ghaziabad: Indian Pharmacopoeia Commission, Government of India, Ministry of Health and Family Welfare.

[75] United States Pharmacopeia and National Formulary (USP-NF). Rockville: United States Pharmacopeial Convention.

[76] Aulton ME, Taylor KMG, editors. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. Edinburgh: Elsevier.

[77] Allen LV, Popovich NG, Ansel HC. Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Wolters Kluwer.

[78] Sweetman SC, editor. Martindale: The Complete Drug Reference. London: Pharmaceutical Press.

[79] National List of Essential Medicines (NLEM) of India. Ministry of Health and Family Welfare, Government of India.

@article{1722920,
      author = {Vicky Banargy, Dr. Rajeev Ranjan, Dr. Dharmendra Kumar},
      title = {Formulation Development and Evaluation of Cost-Effective Sucralfate Oral Suspension: A Comprehensive Review},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {3},
      pages = {892-908},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1722920.pdf},
      abstract = {Sucralfate, a basic aluminium salt of sucrose octasulfate, remains one of the most widely prescribed locally acting cytoprotective agents for peptic ulcer disease, gastro-oesophageal reflux, and radiation- or chemotherapy-induced oral and gastrointestinal mucositis. Because the drug is practically insoluble in water and is required in gram-scale doses, an oral suspension is the pharmaceutical form of choice for patients who cannot swallow tablets, including paediatric, geriatric, post-surgical, and enterally fed patients. This review synthesises current literature on the chemistry, mechanism of action, and clinical indications of sucralfate; the formulation science underlying suspension dosage forms, including the selection of suspending agents, sweeteners, preservatives and buffers; the application of Quality-by-Design (QbD) methodology to rationally engineer a robust suspension; and, most importantly, the strategies available to formulation scientists for developing a sucralfate suspension that is cost-effective without compromising quality, safety, or efficacy. Evaluation parameters recommended for such a suspension, spanning physical, chemical, microbiological, and stability testing consistent with ICH and pharmacopoeial expectations, are discussed and summarised in tabular form. The review concludes that a deliberately planned, low-cost excipient strategy, anchored in QbD principles and rigorous evaluation, can deliver an affordable, stable, and patient-acceptable sucralfate suspension suitable for resource-constrained healthcare settings.},
      keywords = {Sucralfate; oral suspension; cost-effective formulation; suspending agents; Quality by Design; peptic ulcer; oral mucositis; stability evaluation},
      month = {September},
      doi = {https://doi.org/10.64388/IREV10I3-1722920}
  }